证券代码：000790 证券简称：华神科技 公告编号：2025-046 成都华神科技集团股份有限公司 第十三届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（简称"公司"）第十三届董事会第二十六 次会议于2025年11月14日以通讯表决的方式在公司会议室召开，经与全体董事 沟通确认，全体董事同意豁免本次董事会会议的提前通知期限，本次会议通知 于2025年11月14日发出，本次会议应出席董事9人，实际出席董事9人。会议由 公司董事长黄明良先生主持，公司监事、高级管理人员列席了会议。本次会议 的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的有关规定。 二、董事会会议审议情况 根据相关法律法规、规范性文件的最新规定及有关工商管理部门的要求， 公司在2025年10月29日召开的第十三届董事会第二十五次会议审议通过的《公 司章程》的基础上进行了修订。具体内容详见公司同日在巨潮资讯网披露的相 关文件。本议案尚需提交股东会审议。 表决结果：同意9票，反对0票，弃权0 ...

Core Insights - The traditional Chinese medicine sector experienced a slight increase of 0.24% on November 13, with Panlong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Stock Performance Summary - Panlong Pharmaceutical (002864) closed at 39.20, with a significant increase of 9.99% and a trading volume of 237,700 shares, amounting to a transaction value of 864 million [1] - Huasheng Technology (000790) rose by 5.09% to close at 4.54, with a trading volume of 524,900 shares [1] - Tailong Pharmaceutical (600222) saw a 4.91% increase, closing at 7.90 with a trading volume of 793,400 shares [1] - Other notable performers include Te Yi Pharmaceutical (002728) up 3.13% to 13.83, and Enwei Pharmaceutical (301331) up 2.68% to 32.62 [1] Declining Stocks Summary - ST Changyao (300391) decreased by 3.90% to 2.22, with a trading volume of 582,400 shares [2] - ST Huluwa (6655569) fell by 2.34% to 9.62, with a trading volume of 77,100 shares [2] - Weikang Pharmaceutical (300878) dropped by 2.33% to 28.05, with a trading volume of 70,500 shares [2] Capital Flow Analysis - The traditional Chinese medicine sector saw a net outflow of 681 million from main funds, while retail investors contributed a net inflow of 523 million [2]

Core Insights - The Chinese medicine market is experiencing rapid growth, driven by favorable policies and increasing market demand, as highlighted by the recent 12th World Traditional Chinese Medicine Conference held in Sydney, Australia [1][2]. Group 1: Market Performance - As of November 10, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 1.11%, with notable increases in stocks such as Zhongsheng Pharmaceutical (002317) up 3.69% and Kangyuan Pharmaceutical (600557) up 3.22% [1]. - The Traditional Chinese Medicine ETF (159647) increased by 0.88%, with the latest price reported at 1.03 yuan [1]. Group 2: Industry Growth Drivers - The conference attracted over 800 representatives from 24 countries, emphasizing the global interest in the dissemination and technological innovation of traditional Chinese medicine [1]. - Pacific Securities notes that the industry is supported by comprehensive measures across supply, payment, and demand sides, including registration, review, quality control, and cultural promotion [1]. Group 3: Key Constituents - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.92% of the index, including major players like Yunnan Baiyao (000538) and Tongrentang (600085) [2].

Group 1 - The core point of the news is that Huasheng Technology's stock price increased by 6.14% to 4.32 CNY per share, with a trading volume of 88.1 million CNY and a turnover rate of 3.39%, resulting in a total market capitalization of 2.694 billion CNY [1] - Huasheng Technology, established on January 27, 1988, and listed on March 27, 1998, is primarily engaged in the research, production, and sales of traditional Chinese and Western medicines, as well as biopharmaceuticals and steel structure construction [1] - The revenue composition of Huasheng Technology includes 78.26% from traditional Chinese and Western medicines, 17.99% from health drinks and services, 2.57% from other sources, 1.06% from steel structure manufacturing and installation services, and 0.12% from medical devices [1] Group 2 - Among the top ten circulating shareholders of Huasheng Technology, a fund under Huatai-PineBridge is the largest shareholder, having increased its holdings by 1.0127 million shares to a total of 3.886 million shares, representing 0.62% of the circulating shares [2] - The Huatai-PineBridge Zhongzheng Traditional Chinese Medicine ETF (560080) was established on September 26, 2022, with a latest scale of 2.489 billion CNY, and has experienced a loss of 0.83% this year, ranking 4160 out of 4216 in its category [2] - The fund has incurred a loss of 4.25% over the past year, ranking 3840 out of 3913, while achieving a return of 8.25% since its inception [2]

Core Viewpoint - Huasheng Technology, a well-known pharmaceutical company in China, focuses on the research and development of traditional Chinese medicine and biopharmaceuticals, but its financial performance lags behind industry leaders [1][2]. Financial Performance - In Q3 2025, Huasheng Technology reported revenue of 457 million yuan, ranking 57th among 69 companies in the industry, significantly lower than the top performer, Baiyunshan, with 61.606 billion yuan, and Yunnan Baiyao at 30.654 billion yuan [2]. - The company's net profit for the same period was -97.1142 million yuan, placing it 64th in the industry, while Yunnan Baiyao and Baiyunshan reported net profits of 4.789 billion yuan and 3.398 billion yuan, respectively [2]. Financial Ratios - As of Q3 2025, Huasheng Technology's debt-to-asset ratio was 48.98%, slightly higher than the previous year's 48.94% and above the industry average of 32.81% [3]. - The gross profit margin for the same period was 45.48%, down from 47.92% year-on-year and below the industry average of 52.44% [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.50% to 37,000, while the average number of circulating A-shares held per account increased by 5.82% to 16,800 [5]. - Among the top ten circulating shareholders, Huatai-PB Zhongzheng Chinese Medicine ETF ranked eighth with 3.886 million shares, an increase of 1.0127 million shares from the previous period [5]. Executive Compensation - The chairman of Huasheng Technology, Huang Mingliang, received a salary of 799,700 yuan in 2024, an increase of 210,800 yuan compared to 588,900 yuan in 2023 [4].

Core Viewpoint - Huasheng Technology (000790.SZ) reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 457 million yuan, representing a year-on-year decrease of 31.02% [1] - The net profit attributable to shareholders of the listed company was -97.7853 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -72.1513 million yuan [1] - The basic earnings per share were -0.1568 yuan [1]

Group 1 - The company Huasheng Technology (SZ 000790) reported a revenue of approximately 457 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 31.02% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 97.79 million yuan, with a basic earnings per share loss of 0.1568 yuan [1] - As of the report date, the market capitalization of Huasheng Technology was 2.5 billion yuan [1]

成都华神科技集团股份有限公司 董事会议事规则 成都华神科技集团股份有限公司 Chengdu huasun technology group Inc., LTD. 第二条 董事会会议分为定期会议和临时会议。定期会议每年至少召开两次，并可根据需要 召开临时董事会。有下列情形之一的，可召开临时董事会： 第三条 公司召开董事会定期会议，应于会议召开 10 日前发出书面通知。公司召开董事会 临时会议，应于会议召开 2 日前发出书面通知。董事会临时会议可以采用通讯方式进行。紧急情 况下，需要尽快召开董事会临时会议的，在确保全体董事可以出席会议的前提下，会议通知发出 时间可以不受上述限制。 第四条 董事会会议通知应载明以下内容： 第一章 总则 第一条 为健全和规范成都华神科技集团股份有限公司（以下简称"公司"）董事会议事和决 策程序，完善法人治理结构，提高董事会工作效率和科学决策水平，保证公司经营管理工作的顺 利开展，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董事管理 办法》《上市公司治理准则》《深圳证券交易所股票上市规则》等法律法规的规定以及《成都华 神科技集团股份有限公司章程》（以下简称"《 ...

成都华神科技集团股份有限公司 董事、高级管理人员离职管理制度 成都华神科技集团股份有限公司 Chengdu huasun technology group Inc., LTD. 第一章 总则 第一条 为进一步完善成都华神科技集团股份有限公司（以下简称"公司"）董事、高级管 理人员离职管理体系，促进公司健康、持续、稳定发展，根据相关法律、法规和规范性文件及《成 都华神科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定，结合公司实际情 况，制订本制度。 第二条 适用人员：公司董事（含独立董事）、高级管理人员。 第二章 离任情形与程序 第三条 公司董事、 高级管理人员可以在任期届满以前提出辞职。董事、高级管理人员辞 职应向公司提交书面辞职报告。 除法律法规、中国证监会和深圳证券交易所相关规则另有规定外，出现下列规定情形的，在 改选出的董事就任前，原董事仍应当依照法律、行政法规、部门规章和《公司章程》规定，履行 职务： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员低于法定最低人数； （二）审计委员会成员辞任导致审计委员会成员低于法定最低人数，或者欠缺会计专业人士； 第五条 董事、高级管理 ...

第一条 为完善成都华神集团股份有限公司（以下简称"公司"）治理机制，加强内部控制 建设，提高公司年报信息披露编制工作的合规性，充分发挥独立董事在公司年度报告信息披露 中的作用，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券 法》（以下简称《证券法》）、《上市公司独立董事管理办法》《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》等有关法律、法规、规范性文件，以及《成都 华神科技集团股份有限公司章程》（以下简称"《公司章程》"）等规章制度，结合公司年度报 告编制和信息披露工作的实际情况特制订本制度。 第二条 独立董事应在公司年报编制和披露过程中，按照有关法律及《公司章程》的要求， 切实履行独立董事的责任和义务，勤勉尽责地开展工作，维护公司整体利益。 第三条 独立董事应督促公司真实、准确、完整地在年报中披露所有应披露的事项。公司 管理层应配合独立董事做好年报相关工作，保证所提供信息的真实、准确、完整。 第四条 为保证独立董事有效行使职权，公司应当向独立董事通报公司年度财务状况、经 营成果、重大事项等情况，提供相关资料，组织或者配合独立董事开展实地考察等工作。 第五 ...